Published in Semin Immunol on February 01, 2001
Varicella zoster virus glycoprotein E-specific CD4+ T cells show evidence of recent activation and effector differentiation, consistent with frequent exposure to replicative cycle antigens in healthy immune donors. Clin Exp Immunol (2008) 1.19
Further characterization of a rat model of varicella zoster virus-associated pain: Relationship between mechanical hypersensitivity and anxiety-related behavior, and the influence of analgesic drugs. Neuroscience (2006) 1.14
Local immune responses and systemic cytokine responses in zoster: relationship to the development of postherpetic neuralgia. Clin Exp Immunol (2003) 1.00
CD4 T cell immunity is critical for the control of simian varicella virus infection in a nonhuman primate model of VZV infection. PLoS Pathog (2011) 0.98
Varicella zoster virus immune evasion strategies. Curr Top Microbiol Immunol (2010) 0.96
Incidence of herpes zoster in patients with giant cell arteritis: a population-based cohort study. Rheumatology (Oxford) (2010) 0.85
Attenuation of the adaptive immune response in rhesus macaques infected with simian varicella virus lacking open reading frame 61. J Virol (2012) 0.82
Influence of systemic immune and cytokine responses during the acute phase of zoster on the development of postherpetic neuralgia. J Zhejiang Univ Sci B (2009) 0.82
Distinct domains in the adenovirus E3 RIDalpha protein are required for degradation of Fas and the epidermal growth factor receptor. J Virol (2003) 0.80
Identification of an important immunological difference between virulent varicella-zoster virus and its avirulent vaccine: viral disruption of dendritic cell instruction. J Immunol (2010) 0.79
CD4 T cell responses in latent and chronic viral infections. Front Immunol (2013) 0.77
Varicella-Zoster Virus Activates CREB, and Inhibition of the pCREB-p300/CBP Interaction Inhibits Viral Replication In Vitro and Skin Pathogenesis In Vivo. J Virol (2016) 0.75
Identification of women at unsuspected risk of primary infection with herpes simplex virus type 2 during pregnancy. N Engl J Med (1992) 3.91
A controlled trial of acyclovir for chickenpox in normal children. N Engl J Med (1991) 3.78
Prevention of transfusion-acquired cytomegalovirus infections in newborn infants. J Pediatr (1981) 3.42
Outbreak of ceftazidime resistance due to a novel extended-spectrum beta-lactamase in isolates from cancer patients. Antimicrob Agents Chemother (1992) 3.31
Natural history of neonatal herpes simplex virus infections in the acyclovir era. Pediatrics (2001) 2.91
Tropism of varicella-zoster virus for human CD4+ and CD8+ T lymphocytes and epidermal cells in SCID-hu mice. J Virol (1995) 2.87
The varicella-zoster virus immediate-early protein IE62 is a major component of virus particles. J Virol (1992) 2.80
Intrauterine infection with varicella-zoster virus after maternal varicella. N Engl J Med (1986) 2.63
Attenuation of the vaccine Oka strain of varicella-zoster virus and role of glycoprotein C in alphaherpesvirus virulence demonstrated in the SCID-hu mouse. J Virol (1998) 2.48
Varicella vaccine in pregnancy. BMJ (1996) 2.38
Mutational analysis of the role of glycoprotein I in varicella-zoster virus replication and its effects on glycoprotein E conformation and trafficking. J Virol (1997) 2.34
Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections. Pediatrics (2001) 2.30
The ORF47 and ORF66 putative protein kinases of varicella-zoster virus determine tropism for human T cells and skin in the SCID-hu mouse. Proc Natl Acad Sci U S A (1998) 2.22
Reliability of a history of previous varicella infection in adults. JAMA (1997) 2.13
Low risk of herpes simplex virus infections in neonates exposed to the virus at the time of vaginal delivery to mothers with recurrent genital herpes simplex virus infections. N Engl J Med (1987) 1.99
Varicella-zoster virus gE escape mutant VZV-MSP exhibits an accelerated cell-to-cell spread phenotype in both infected cell cultures and SCID-hu mice. Virology (2000) 1.99
Failure of antepartum maternal cultures to predict the infant's risk of exposure to herpes simplex virus at delivery. N Engl J Med (1986) 1.94
Immune responses to measles and mumps vaccination of infants at 6, 9, and 12 months. J Infect Dis (2001) 1.90
Deficiency of the humoral immune response to measles vaccine in infants immunized at age 6 months. JAMA (1998) 1.83
Frequencies of memory T cells specific for varicella-zoster virus, herpes simplex virus, and cytomegalovirus by intracellular detection of cytokine expression. J Infect Dis (2000) 1.81
Early immune response in healthy and immunocompromised subjects with primary varicella-zoster virus infection. J Infect Dis (1986) 1.72
Use of routine viral cultures at delivery to identify neonates exposed to herpes simplex virus. N Engl J Med (1988) 1.67
Application of the polymerase chain reaction to the diagnosis and management of neonatal herpes simplex virus disease. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. J Infect Dis (1996) 1.66
Detection of type-specific antibody to herpes simplex virus type 1 by radioimmunoassay with herpes simplex virus type 1 glycoprotein C purified with monoclonal antibody. Infect Immun (1983) 1.65
Investigation of varicella-zoster virus infection of lymphocytes by in situ hybridization. J Virol (1989) 1.64
Essential role played by the C-terminal domain of glycoprotein I in envelopment of varicella-zoster virus in the trans-Golgi network: interactions of glycoproteins with tegument. J Virol (2001) 1.55
Mutational analysis of the repeated open reading frames, ORFs 63 and 70 and ORFs 64 and 69, of varicella-zoster virus. J Virol (2001) 1.53
Cell-mediated immunity of cytomegalovirus infection in normal subjects and cardiac transplant patients. J Infect Dis (1978) 1.51
Cellular and humoral immunity in the pathogenesis of recurrent herpes viral infections in patients with lymphoma. J Clin Invest (1980) 1.48
The management of pregnancies complicated by genital infections with herpes simplex virus. Clin Infect Dis (1992) 1.45
Investigation of varicella-zoster virus infection by polymerase chain reaction in the immunocompetent host with acute varicella. J Infect Dis (1991) 1.43
Immunoglobulins M and G to varicella-zoster virus measured by solid-phase radioimmunoassay: antibody responses to varicella and herpes zoster infections. J Clin Microbiol (1980) 1.41
Selective impairment of lymphocyte reactivity to varicella-zoster virus antigen among untreated patients with lymphoma. J Infect Dis (1978) 1.40
Varicella-zoster virus retains major histocompatibility complex class I proteins in the Golgi compartment of infected cells. J Virol (2001) 1.36
Modulation of major histocompatibility class II protein expression by varicella-zoster virus. J Virol (2000) 1.30
Type-specific antibodies to herpes simplex virus type 2 (HSV-2) glycoprotein G in pregnant women, infants exposed to maternal HSV-2 infection at delivery, and infants with neonatal herpes. J Infect Dis (1988) 1.29
IL-12, IFN-gamma, and T cell proliferation to measles in immunized infants. J Immunol (1999) 1.28
Subclinical varicella-zoster virus viremia, herpes zoster, and T lymphocyte immunity to varicella-zoster viral antigens after bone marrow transplantation. J Infect Dis (1992) 1.26
Fusarium brain abscess. Case report. J Neurosurg (1983) 1.17
Use of polymerase chain reaction for successful identification of asymptomatic genital infection with herpes simplex virus in pregnant women at delivery. J Infect Dis (1990) 1.17
Immunologic evidence of reinfection with varicella-zoster virus. J Infect Dis (1983) 1.16
T lymphocyte cytotoxicity with natural varicella-zoster virus infection and after immunization with live attenuated varicella vaccine. J Immunol (1989) 1.15
Immunity to varicella-zoster viral glycoproteins, gp I (gp 90/58) and gp III (gp 118), and to a nonglycosylated protein, p 170. J Immunol (1986) 1.15
Relationship of antibody to outcome in neonatal herpes simplex virus infections. Infect Immun (1980) 1.12
Neonatal antibody-dependent cellular cytotoxic antibody levels are associated with the clinical presentation of neonatal herpes simplex virus infection. J Infect Dis (1989) 1.08
Reasons for the absence of a history of recurrent genital infections in mothers of neonates infected with herpes simplex virus. Pediatrics (1984) 1.08
Human leukocyte interferon in the treatment of varicella in children with cancer: a preliminary controlled trial. Antimicrob Agents Chemother (1978) 1.08
Effect of leukocyte interferon on urinary excretion of cytomegalovirus by infants. J Infect Dis (1976) 1.06
Humoral and cell-mediated immunity in neonates with herpes simplex virus infection. J Infect Dis (1987) 1.06
Pharmacokinetics of acyclovir in the term human pregnancy and neonate. Am J Obstet Gynecol (1991) 1.05
Varicella-zoster virus infection of a human CD4-positive T-cell line. Virology (2000) 1.04
Interleukin (IL)-10, IL-12, and interferon-gamma production in primary and memory immune responses to varicella-zoster virus. J Infect Dis (1998) 1.04
The epidemiology of neonatal herpes simplex virus infections in California from 1985 to 1995. J Infect Dis (1999) 1.04
Human leukocyte interferon for the treatment of varicella in children with cancer. N Engl J Med (1982) 1.02
Kinetics and viral protein specificity of the cytotoxic T lymphocyte response in healthy adults immunized with live attenuated varicella vaccine. J Infect Dis (1992) 1.02
Early reconstitution of immunity and decreased severity of herpes zoster in bone marrow transplant recipients immunized with inactivated varicella vaccine. J Infect Dis (1997) 1.01
Glycoprotein E of varicella-zoster virus enhances cell-cell contact in polarized epithelial cells. J Virol (2000) 1.00
Neonatal herpes simplex infection in the absence of mucocutaneous lesions. J Pediatr (1982) 1.00
Acyclovir treatment for varicella does not lower gpI and IE-62 (p170) antibody responses to varicella-zoster virus in normal children. J Clin Microbiol (1990) 0.99
Analysis of the persistence of humoral and cellular immunity in children and adults immunized with varicella vaccine. J Infect Dis (1998) 0.99
Analysis of the glycoproteins I and E of varicella-zoster virus (VZV) using deletional mutations of VZV cosmids. J Infect Dis (1998) 0.98
Specific cell-mediated immunity and infections with herpes viruses in cardiac transplant recipients. Am J Med (1982) 0.98
Immunity in strain 2 guinea-pigs inoculated with vaccinia virus recombinants expressing varicella-zoster virus glycoproteins I, IV, V or the protein product of the immediate early gene 62. J Gen Virol (1992) 0.96
Varicella-zoster virus IE63, a virion component expressed during latency and acute infection, elicits humoral and cellular immunity. J Infect Dis (1998) 0.95
Recognition of the latency-associated immediate early protein IE63 of varicella-zoster virus by human memory T lymphocytes. J Immunol (1997) 0.92
Genital herpes and the pregnant woman. Curr Clin Top Infect Dis (1989) 0.91
Serum immunoglobulin A antibody to varicella-zoster virus in subjects with primary varicella and herpes zoster infections and in immune subjects. J Clin Microbiol (1983) 0.91
Investigation of the pathogenesis of varicella-zoster virus infection in guinea pigs by using polymerase chain reaction. J Infect Dis (1993) 0.90
T cell recognition and cytokine production elicited by common and type-specific glycoproteins of herpes simplex virus type 1 and type 2. J Infect Dis (1996) 0.90
Age-related differences in cell-mediated immunity to varicella-zoster virus among children and adults immunized with live attenuated varicella vaccine. J Infect Dis (1995) 0.90
Granulysin blocks replication of varicella-zoster virus and triggers apoptosis of infected cells. Viral Immunol (2001) 0.89
Sensitivity of different assay systems for immunoglobulin M responses to varicella-zoster virus in reactivated infections (zoster). J Clin Microbiol (1986) 0.87
Pharmacokinetics of acyclovir suspension in infants and children. Antimicrob Agents Chemother (1987) 0.86
Herpes simplex virus type 2--a persistent problem. N Engl J Med (1997) 0.86
Major histocompatibility complex restriction of T-cell responses to varicella-zoster virus in guinea pigs. J Virol (1991) 0.86
The immunogenicity of the Oka/Merck varicella vaccine in relation to infectious varicella-zoster virus and relative viral antigen content. J Infect Dis (1990) 0.86
Human T cells recognize multiple epitopes of an immediate early/tegument protein (IE62) and glycoprotein I of varicella zoster virus. Viral Immunol (1991) 0.85
Interferon prophylaxis against simian varicella in Erythrocebus patas monkeys. J Infect Dis (1983) 0.85
A prospective evaluation of primary genital herpes simplex virus type 2 infections acquired during pregnancy. Pediatr Infect Dis J (1990) 0.84
Safety and immunogenicity of one vs. two injections of Oka/Merck varicella vaccine in healthy children. Pediatr Infect Dis J (1996) 0.84
Comparison of primary sensitization of naive human T cells to varicella-zoster virus peptides by dendritic cells in vitro with responses elicited in vivo by varicella vaccination. J Immunol (1999) 0.83
Nocardia farcinica pneumonia in chronic granulomatous disease. Pediatrics (1999) 0.83
Immunity to whole varicella-zoster virus antigen and glycoproteins I and p170: relation to the immunizing regimen of live attenuated varicella vaccine. J Infect Dis (1988) 0.83
Neonatal aspergillosis. A case report and review of the literature. Clin Pediatr (Phila) (1986) 0.82
Detection of antibodies to herpes simplex virus type 2 with a mammalian cell line expressing glycoprotein gG-2. Clin Diagn Virol (1993) 0.82
Isolation and utilization of human dendritic cells from peripheral blood to assay an in vitro primary immune response to varicella-zoster virus peptides. J Infect Dis (1998) 0.82
Comparison of varicella zoster antibody titers in patients given intravenous immune serum globulin or varicella zoster immune globulin. J Pediatr (1984) 0.82
Human monoclonal antibodies neutralizing varicella-zoster virus. J Infect Dis (1985) 0.81
Acid labile alpha-interferon in sera and synovial fluids from patients with juvenile arthritis. Arthritis Rheum (1984) 0.81
Varicella vaccine--the first six years. N Engl J Med (2001) 0.81
The effect of chronologic age on the serum concentrations of amikacin in sick term and premature infants. J Pediatr (1981) 0.81
Tumor necrosis factor, interleukin-2, and interferon-gamma in adult varicella. J Med Virol (1994) 0.80
Antiviral susceptibilities of herpes simplex virus isolates from infants with recurrent mucocutaneous lesions after neonatal infection. Pediatr Infect Dis J (1989) 0.80
Perinatal viral infections. Eur J Clin Microbiol (1987) 0.80
Multifocal leukoencephalitis caused by varicella-zoster virus in a child with leukemia: successful treatment with acyclovir. Pediatr Infect Dis J (1993) 0.80
A concurrent epidemic of respiratory syncytial virus and echovirus 7 infections in an intensive care nursery. Pediatr Infect Dis J (1989) 0.79
Treatment of adult varicella with sorivudine: a randomized, placebo-controlled trial. J Infect Dis (1996) 0.79
Lack of transmission of the live attenuated varicella vaccine virus to immunocompromised children after immunization of their siblings. Pediatrics (1991) 0.79
Immunization with the immediate-early tegument protein (open reading frame 62) of varicella-zoster virus protects guinea pigs against virus challenge. J Virol (1993) 0.79
Investigation of varicella-zoster virus infection by polymerase chain reaction in the immunocompetent host with acute varicella. J Infect Dis (1992) 0.78